STAAR Surgical (NASDAQ:STAA) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its position in shares of STAAR Surgical (NASDAQ:STAA – Get Rating) by 66.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,443 shares of the medical instruments supplier’s stock after selling 82,696 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.09% of STAAR Surgical worth $2,002,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of STAAR Surgical by 0.6% during the 1st quarter. BlackRock Inc. now owns 5,654,613 shares of the medical instruments supplier’s stock valued at $451,861,000 after acquiring an additional 31,657 shares during the last quarter. Baillie Gifford & Co. boosted its position in shares of STAAR Surgical by 2.2% during the 4th quarter. Baillie Gifford & Co. now owns 5,240,456 shares of the medical instruments supplier’s stock valued at $254,372,000 after acquiring an additional 112,653 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of STAAR Surgical by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 5,218,432 shares of the medical instruments supplier’s stock valued at $368,160,000 after acquiring an additional 55,639 shares during the last quarter. State Street Corp boosted its position in shares of STAAR Surgical by 3.2% during the 1st quarter. State Street Corp now owns 1,570,063 shares of the medical instruments supplier’s stock valued at $125,464,000 after acquiring an additional 48,083 shares during the last quarter. Finally, Kayne Anderson Rudnick Investment Management LLC boosted its position in shares of STAAR Surgical by 8.1% during the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 660,813 shares of the medical instruments supplier’s stock valued at $46,621,000 after acquiring an additional 49,691 shares during the last quarter. Institutional investors and hedge funds own 97.55% of the company’s stock.

STAAR Surgical Stock Performance

Shares of STAA opened at $63.29 on Monday. The stock has a market capitalization of $3.06 billion, a PE ratio of 98.89 and a beta of 1.23. STAAR Surgical has a 1 year low of $46.35 and a 1 year high of $112.27. The company’s 50-day simple moving average is $65.02 and its 200-day simple moving average is $63.21.

STAAR Surgical (NASDAQ:STAA – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.02). STAAR Surgical had a return on equity of 9.85% and a net margin of 10.81%. The business had revenue of $64.04 million for the quarter, compared to analyst estimates of $64.37 million. On average, sell-side analysts predict that STAAR Surgical will post 0.57 earnings per share for the current year.

Insider Buying and Selling

In related news, CTO Keith Holliday sold 823 shares of the company’s stock in a transaction that occurred on Friday, March 17th. The shares were sold at an average price of $61.97, for a total transaction of $51,001.31. Following the sale, the chief technology officer now directly owns 27,633 shares in the company, valued at $1,712,417.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

STAA has been the topic of a number of recent analyst reports. Piper Sandler initiated coverage on shares of STAAR Surgical in a research report on Monday, April 17th. They issued a “neutral” rating and a $65.00 target price on the stock. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $79.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, January 30th. Needham & Company LLC upped their target price on shares of STAAR Surgical from $78.00 to $84.00 in a research report on Thursday, May 4th. BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Monday, February 6th. Finally, Stephens reaffirmed an “overweight” rating and issued a $85.00 target price on shares of STAAR Surgical in a research report on Wednesday, February 22nd. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.18.

STAAR Surgical Profile

(Get Rating)

STAAR Surgical Co engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens.